Chemotherapy Induced Neutropenia, 2019 – Pipeline Review, H2 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chemotherapy Induced Neutropenia – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The Publisher’s Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Neutropenia – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Neutropenia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 6, 1, 5, 9, 6 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Chemotherapy Induced Neutropenia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia (Toxicology).
• The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Chemotherapy Induced Neutropenia (Toxicology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Chemotherapy Induced Neutropenia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (Toxicology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Report Coverage
• Chemotherapy Induced Neutropenia – Overview
• Chemotherapy Induced Neutropenia – Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Chemotherapy Induced Neutropenia – Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Chemotherapy Induced Neutropenia – Companies Involved in Therapeutics Development
• BeyondSpring Inc
• Biocon Ltd
• Bolder Biotechnology Inc
• Cellerant Therapeutics Inc
• Chong Kun Dang Pharmaceutical Corp
• Dr. Reddy’s Laboratories Ltd
• Enzychem Lifesciences Corp
• Gene Techno Science Co Ltd
• Generon (Shanghai) Corp Ltd
• GlycoMimetics Inc
• Hanmi Pharmaceuticals Co Ltd
• Lupin Ltd
• Mycenax Biotech Inc
• Nohla Therapeutics Inc
• Pangen Biotech Inc
• Pfizer Inc
• PharmaEssentia Corp
• Profarma
• Prolong Pharmaceuticals LLC
• Richter Gedeon Nyrt
• Tanvex BioPharma Inc
• USV Pvt Ltd
• Valenta Pharm
• Chemotherapy Induced Neutropenia – Drug Profiles
• BBT-007 – Drug Profile
• BBT-015 – Drug Profile
• Cell Therapy for Chemotherapy Induced Neutropenia – Drug Profile
• dilanubicel – Drug Profile
• eflapegrastim – Drug Profile
• F-627 – Drug Profile
• filgrastim – Drug Profile
• GR-007 – Drug Profile
• GW-003 – Drug Profile
• GXG-3 – Drug Profile
• lenograstim – Drug Profile
• mosedipimod – Drug Profile
• Myelo-001 – Drug Profile
• pegfilgrastim – Drug Profile
• plinabulin – Drug Profile
• romyelocel-L – Drug Profile
• SFR-9314 – Drug Profile
• UB-853 – Drug Profile
• uproleselan sodium – Drug Profile
• YPEG-Filgrastim – Drug Profile
• Chemotherapy Induced Neutropenia – Dormant Projects
• Chemotherapy Induced Neutropenia – Discontinued Products
• Chemotherapy Induced Neutropenia – Product Development Milestones
• Featured News & Press Releases

Companies Mentioned

• BeyondSpring Inc
• Biocon Ltd
• Bolder Biotechnology Inc
• Cellerant Therapeutics Inc
• Chong Kun Dang Pharmaceutical Corp
• Dr. Reddy’s Laboratories Ltd
• Enzychem Lifesciences Corp
• Gene Techno Science Co Ltd
• Generon (Shanghai) Corp Ltd
• GlycoMimetics Inc
• Hanmi Pharmaceuticals Co Ltd
• Lupin Ltd
• Mycenax Biotech Inc
• Nohla Therapeutics Inc
• Pangen Biotech Inc
• Pfizer Inc
• PharmaEssentia Corp
• Profarma
• Prolong Pharmaceuticals LLC
• Richter Gedeon Nyrt
• Tanvex BioPharma Inc
• USV Pvt Ltd
• Valenta Pharm

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/1rm1ol

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900